Top-News
Dienstag,
09.05.2017 22:10
von
PR Newswire
| Aufrufe: 29
Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results
Eine Apothekerin (Symbolfoto).
©
PR Newswire
DUBLIN, May 9, 2017
DUBLIN, May 9, 2017 /PRNewswire/ --
Total Revenues Increased 12% to $376 Million
Settled Xyrem Patent Litigation with First ANDA Filer
Completed Rolling NDA Submission for Vyxeos (CPX-351)
Announced Positive Top-Line Data for JZP-110 in Obstructive Sleep Apnea and Narcolepsy and for Xyrem in Pediatric Narcolepsy
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2017 and updated financial guidance for 2017.
"The first part of 2017 has been an exceptionally productive period for us in R&D as we announced top-line data for our three JZP-110 Phase 3 studies and our Xyrem Phase 2/3 pediatric study, completed the Vyxeos NDA submission while preparing for potential FDA approval and launch, started additional clinical programs and advanced other key development projects," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "With increased clarity around Xyrem longevity, we remain focused on delivering on our growth strategy, including preparing for the launch of additional products, such as Vyxeos, and investing in corporate development activities with the goal of further diversifying and expanding our product portfolio and offering important new therapeutic options to patients while increasing shareholder value."
ARIVA.DE Börsen-Geflüster
Werbung
Weiter aufwärts?
| Kurzfristig positionieren in Jazz Pharmaceuticals | ||
|
ME2X7G
| Ask: 1,28 | Hebel: 4,14 |
| mit moderatem Hebel |
Zum Produkt
| |
Morgan Stanley
Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie hier: ME2X7G,. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Kurse
 |
GAAP net income for the first quarter of 2017 was $86.5 million, or $1.41 per diluted share, compared to $75.8 million, or $1.21 per diluted share, for the first quarter of 2016.
Adjusted net income for the first quarter of 2017 was $141.2 million, or $2.31 per diluted share, compared to $134.6 million, or $2.15 per diluted share, for the first quarter of 2016. Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Financial Highlights
| | Three Months Ended March 31, | | | |||||||
| (In thousands, except per share amounts and percentages) | 2017 | | 2016 | | Change | |||||
| Total revenues | $ | 376,053 | | | $ | 336,010 | | | 11.9 | % |
| GAAP net income | $ | 86,511 | | | $ | 75,812 | | | 14.1 | % |
| Adjusted net income | $ | 141,222 | | | $ | 134,568 | | | 4.9 | % |
| GAAP EPS | $ | 1.41 | | | $ | 1.21 | | | 16.5 | % |
| Adjusted EPS | $ | 2.31 | | | $ | 2.15 | | | 7.4 | % |
Total Revenues
| | Three Months Ended | ||||||
| (In thousands) | 2017 | | 2016 | ||||
| Xyrem® (sodium oxybate) oral solution | $ | 272,326 | | | $ | 249,537 | |
| Erwinaze® / Erwinase® (asparaginase Erwinia chrysanthemi) | 51,388 | | | 51,173 | | ||
| Defitelio® (defibrotide sodium) / defibrotide | 35,900 | | | 17,897 | | ||
| Prialt® (ziconotide) intrathecal infusion | 7,717 | | | 6,209 | | ||
| Other | 6,347 | | | 9,100 | | ||
| Product sales, net | 373,678 | | | 333,916 | | ||
| Royalties and contract revenues | 2,375 | | | 2,094 | | ||
| Total revenues | $ | 376,053 | | | $ | 336,010 | |
Net product sales increased 12% in the first quarter of 2017 compared to the same period in 2016 primarily due to higher net product sales of Xyrem and Defitelio.
Xyrem net product sales increased 9% in the first quarter of 2017 compared to the same period in 2016.
Erwinaze/Erwinase net product sales in the first quarter of 2017 were consistent with net product sales in the same period in 2016. During the quarter, the company continued to experience supply challenges, which resulted in fluctuations in inventory levels and temporary disruptions to the company's ability to supply certain markets. The company expects that temporary supply disruptions will continue in 2017, including in the U.S.
Defitelio/defibrotide net product sales increased 101% in the first quarter of 2017 compared to the same period in 2016 primarily due to the launch of Defitelio in the U.S. in April 2016 and strong growth in sales in other markets. Net product sales in the U.S. were $11.6 million in the first quarter of 2017.
Operating Expenses
| | Three Months Ended | ||||||
| (In thousands, except percentages) | 2017 | | 2016 | ||||
| GAAP: | | | | ||||
| Cost of product sales | $ | 25,065 | | | $ Werbung Mehr Nachrichten zur Jazz Pharmaceuticals Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1  Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Andere Nutzer interessierten sich auch für folgende News | ||
